Simon Pacey

Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G2–M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.

Year:

2025

Year:

2025

Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G 2 –M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.

Year:

2025

Gemcitabine plus cisplatin (GC) is effective in urothelial and other cancers. We investigated GC combined with escalating doses of temsirolimus (T), intravenous mTOR inhibitor. Adults with histologically confirmed solid tumours were enrolled. The primary endpoint was safety of GC with T, including dose limiting toxicity. Exploratory endpoints included pharmacokinetics and circulating tumour DNA (ctDNA) analyses. Fourteen participants (6 bladder cancer) were enrolled. Four dose levels were evaluated, adverse events were common and led to dose reductions, delays and omissions. Plasma concentrations of gemcitabine metabolites and cisplatin were unaffected by temsirolimus. ctDNA was detected in all samples taken from a sub set of patients. Levels of ctDNA changed earlier and correlated with imaging, while biologically relevant mutations e.g. PIK3CA were detected. Our results confirm the poor tolerability of three-drug combinations including GC and T but highlight the potential for ctDNA monitoring in Phase 1 cancer trials.

Year:

2025

The prospective, single-arm CALIBRATION trial (NCT03653052) assessed liquid biopsies for early response concordance compared with CT scan assessment in patients with advanced oesophageal cancer given durvalumab (PD-L1 inhibitor) after at least one prior systemic therapy. 19 participants received 1500mg of durvalumab every four weeks. ctDNA was analysed retrospectively with Guardant 360 ® CDx at baseline, weeks 4 and 7. Response at week 26 was assessed by RECIST v1.1. Tumour samples underwent 30X Whole Genome Sequencing. Concordance between ctDNA and CT results was pre-defined as either ≥50% increase in ctDNA mean variant allele frequency (VAF) with progressive disease, or ≥50% decrease in VAF correlating with radiological response or stable disease. At week four, 4/17 patients (23.5%) showed concordance; at week seven, this rose to 6/12 patients (50.0%). We reduced ctDNA VAF thresholds sequentially from ±50% to ±1% and identified that with any change in ctDNA at week 7, 75% of cases (9/12) showed concordance. 14/18 (77.7%) of patients progressed in the cohort at 6 months. All patients with ctDNA increases progressed. Our data supports assessing ctDNA at week seven rather than week four for immunotherapy response prediction. ctDNA VAF increases, especially, could aid decision-making in early-phase clinical trials to cease non-beneficial interventions.

Year:

2024

Year:

2023

Collaborators (12)

Vincent J. Gnanapragasam

Professor of Urology

University of Cambridge

UNITED KINGDOM
View details

Robert Jones

University of Glasgow

UNITED KINGDOM
View details

Javier García-Corbacho

Head of Early Drug Development Unit

-

SPAIN
View details

Tamsin Robb

Research Associate

University of Cambridge

UNITED KINGDOM
View details

Mark Linch

Associate Professor of Oncology

-

UNITED KINGDOM
View details

Paul Loadman

Professor of Drug Metabolism and Pharmacokinetics

University of Bradford

UNITED KINGDOM
View details

Amit Roshan

Clinical Senior Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Daniel Brewer

Professor of Medical Bioinformatics and Genomics

University of East Anglia

UNITED KINGDOM
View details

Richard Baird

Clinical Research Professor in Breast Cancer Therapeutics

University of Cambridge

UNITED KINGDOM
View details

Tristan Barrett

-

UNITED KINGDOM
View details

Greg Shaw

Honorary Associate Professor

University College London

UNITED KINGDOM
View details

ANNE WARREN

Associate Lecturer

University of Cambridge

UNITED KINGDOM
View details